| Gene symbol | IL13RA2 | Synonyms | CD213A2, CT19, IL-13R, IL13BP | Type of gene | protein-coding |
| Chromosome | X | Map location | Xq23 | dbXrefs | |
| Gene perturbation-related omics dataset | PerturbAtlas | ||||
| Description | interleukin 13 receptor subunit alpha 2 | ||||
| GTO ID | GTC3842 |
| Trial ID | NCT06355908 |
| Disease | Glioma |
| Altered gene | IL13RA2 |
| Therapeutic/Target gene | Target gene |
| Therapy | CAR-T cell |
| Treatment | IL13Ra2 CAR-T cells |
| Phase | Phase1 |
| Recruitment status | Recruiting |
| Title | Safety, Tolerability and Efficacy of Enhanced IL-13Rα2 Targeted Chimeric Antigen Receptor T Cell Immunotherapy Against Recurrent/Refractory Grade 4 Glioma |
| Year | 2024 |
| Country | China |
| Company sponsor | Yang Zhang |
| Other ID(s) | TT002 |
| Cohort 1 | |||||||
|
|||||||